Avelumab for Urothelial Carcinoma - Improving Overall Survival

Avelumab for Urothelial Carcinoma - Improving Overall Survival is organized by Connect Educate Impact (CEI).

Initial Release Date: September 8, 2021
Planned Expiration Date: September 8, 2024

Description:
Treatment of inoperable, locally advanced, or metastatic urothelial cancer usually centers on systemic platinum-based chemotherapy. This month's journal club reviews data on new antibody therapies that may prolong survival in these patients.

Objectives:
Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
• Describe the pathophysiology of urothelial cancer
• Discuss the current standard treatment options for locally advanced or metastatic urothelial cancer (Ia/MUC)
• Analyze the current evidence on the safety and efficacy of anti-PD-L1 antibody treatment for Ia/mUC
• Assess strengths and limitations of a recent phase 3 study evaluating avelumab in Ia/mUC
• Develop a conclusion for the clinical appropriateness of care based on a clinical trial